NCT00436241View on ClinicalTrials.gov

A Study of Xeloda (Capecitabine) as First-Line Chemotherapy in Patients With Advanced or Metastatic Gastric Cancer.

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Gastric Cancer
Interventions
DRUG

Oxaliplatin

85mg/m2 iv on day 1 of each 2 week cycle

DRUG

capecitabine [Xeloda]

1000mg/m2 po bid on days 1-10 of each 2 week cycle

Trial Locations (13)

106

Taipei

110

Taipei

204

Keelung

265

Yilan

333

Taoyuan District

404

Taichung

407

Taichung

613

Chai Yi

622

Chai Yi

704

Tainan City

710

Tainan City

807

Kaohsiung City

00112

Taipei

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00436241 - A Study of Xeloda (Capecitabine) as First-Line Chemotherapy in Patients With Advanced or Metastatic Gastric Cancer. | Biotech Hunter | Biotech Hunter